European Lead Factory (EU Lead Factory)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • No disease focus
ELF Logo072013

Abstract

The European Lead Factory (EU Lead Factory) is a pan-European platform for drug discovery supported by the Innovative Medicines Initiative (IMI) that is set to give a major boost to drug discovery in Europe. Comprising a collection of half a million compounds (derived from new public and existing private company collections) and a screening centre, the European Lead Factory will offer researchers in academia, small and medium-sized enterprises (SMEs) and patient organizations an unprecedented opportunity to advance medical research and develop new medicines. ELF intended duration is 60 months until December 31st, 2017.

The objective: a collaborative approach to find small molecule candidates.
The ELF was established in 2013 to find valuable lead candidates that were previously inaccessible – compounds that can result in the development of novel treatment options for patients. To achieve this goal, the ELF provides a high-quality compound library and the opportunity to screen those compounds against potential drug targets to the broader community.

High-quality compounds
In an unprecedented joint-force approach, seven members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) decided to give the European research community and each other access to their heavily safe-guarded compound libraries. By contributing over 300,000 compounds to the Joint European Compound Library (JECL), they aim to boost drug discovery within Europe. One of the objectives of the ELF is to complement these by another 200,000 innovative compounds, synthesized specifically for the JECL by the Public Chemistry Consortium. To achieve this, library design proposals are being sourced from academic groups and Small- and Medium-sized Enterprises (SMEs) throughout a European crowd sourcing approach. Together, the EFPIA and Public compound collection will form the unique 500,000-strong JECL. All efforts of the Chemistry Consortium in delivering up to 200,000 novel compounds to subsequent screening activities are managed by Taros Chemicals.

Screening opportunities
The ultimate deliverable of ELF is to provide the highest quality lead candidates to stimulate drug discovery programmes. To find valuable lead structures, the compounds in the JECL are screened against drug targets by means of ultra-high throughput (uHTS) screening at eight screening centres: at each of the seven participating EFPIA partners, and at the European Screening Centre (ESC). The ELF allows the seven EFPIA companies to access the full JECL for a limited number of their screening programmes. In addition, the ESC provides European researchers in- and outside the consortium the unique opportunity to screen their potential drug target against the JECL. Interested researchers can apply for a screening slot in a rolling review and selection process.

Partnerships
The European Lead Factory is based on a partnership of 30 organizations throughout Europe and welcomes the opportunity to collaborate with you to advance drug discovery even further. Within the project, crowd sourcing provides not only a constant flow of innovation but also new opportunities for collaborations between academic groups, SMEs and EFPIA members on both scientific and commercial grounds.

Learn more about the European Lead Factory on YouTube: https://youtu.be/YLnSi_3o2U8

Consortium History

2013: ELF start date
2013: ELF opens for proposals
2014: ELF releases first results confirming drug discovery potential
2014 August: ELF now supports target assays with Ca2+ readout as well
2014 November: First SME receives Qualified Hit List
2015 January: Almost 40.000 novel compounds synthesized and delivered into the JECL for uHTS, 1st publication on the character of the Joint European Compound Library (JECL)
2015 April: ELF wins BIO-IT World Best Practices Award for its Honest Data Broker implementation of ScienceCloud
2015 April: Over 50,000 compounds successfully synthesized and added to the JECL
2015 August: Over 50 public target programmes have now been accepted for screening at the European Lead Factory
2015 September: ELF launches revised website, more than 20 publications relating to ELF

Structure & Governance

EU Lead Factory is governed by the Project Management Board and the Project General Assembly. The Program Office at TI Pharma (see www.tipharma.com) is responsible for scientific management. All project management services are provided by GABO:mi (see www.gabo-mi.com). The Project Executive team consisting of the three members Bayer Pharma (see: www.bayer.com , ELF coordinator), Taros Chemicals (see: www.tarosdiscovery.com, Chemistry) and TI Pharma (Biology) acts as the decision making body. 

Financing

EU Lead Factory is funded under the European Innovative Medicines Initiative (IMI). The total project budget is around €196.5 million, with €80.0 million from the European Commission and €91.3 million of in kind contributions from EFPIA members. A further €25.2 million comes from non-EFPIA participants.

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

All experimental work is supported by IMI funding, and target program owners receive a Qualified Hit List (QHL) of up to 50 compounds, complete with relevant information to help in the development of an Improved Hit List (IHL).

Target program owners have exclusive access (within EU Lead Factory) to threshold active compounds in their QHL and do not have to disseminate screening results at this time. They are free to decide whether results will be exploited directly or used for further research. After the three-year exclusivity period, QHL/IHL information will be made public.

Milestone payments are due if direct exploitation proceeds, not for research use. Owners and contributors will give EFPIA members the right to submit a first bid (which they do not have to accept).

Impact/Accomplishment

Updated news can be found at https://www.europeanleadfactory.eu/results/news/

Points of Contact

Stefan Jaroch
Bayer Pharma
phone: +49 30 468 194790
email: stefan.jaroch@bayer.com

Ton Rijnders
TI Pharma
phone: +31 71 332 2035
email: ton.rijnders@tipharma.com

Dimitrios Tzalis
Taros
phone: +49 231 97 427211
email: dtzalis@taros.de

Sponsors & Partners

AstraZeneca

BioAscent

ChemAxon

University of Dundee

Edelris

GABO:mi

H. Lundbeck A/S

Janssen Pharmaceutica NV

Lead Discover Center GmbH

Leiden University

Max Planck Institute of Molecular Physiology

Mercachem B.V.

Merck KGaA

Netherlands Cancer Institute

Pivot Park Screening Centre (PPSC)

Radboud University Nijmegen, Institute for Molecules and Materials

Rijksuniversiteit Groningen, Department for Drug Design

Sanofi Aventis Deutschland GmbH

Sygnature Discovery Ltd.

Syncom BV

Taros Chemicals GmbH & Co. KG

Technical University of Denmark

The Bayer Group

TI Pharma

UCB Pharma SA

University of Duisburg-Essen

University of Leeds

University of Nottingham

University of Oxford

VU University Amsterdam


Last Updated: 05/24/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.